Is men's health just a single letter?

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages 70-72

  Anawalt, Bradley D ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; ANDROGEN THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TESTOSTERONE BLOOD LEVEL;

DIHYDROTESTOSTERONE; ESTRADIOL; HUMANS; MALE; MYOCARDIAL ISCHEMIA; TESTOSTERONE;

EID: 84892189342     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4362     Document Type: Review

References (18)

1. Handelsman DJ. Global trends in testosterone prescribing, 2000- 2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199:548-551.
2. The Coronary Drug Project. The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA. 1970;214:1303-1313.
3. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The Coronary Drug Project Research Group. JAMA. 1973;226:652-657.
4. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313-340.
5. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050-2058.
6. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
7. Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014;99:E9-E18.
8. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
9. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006;91:3850-3856.
10. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351-2361.
11. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
12. Khosla S, Melton LJ 3rd, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab. 2002;87:1443-1450.
13. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369:1011-1022.
14. Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010; 10:CD006015.
15. Amory JK, Wang C, Swerdloff RS, et al. The effect of 5α-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007; 92:1659-1665.
16. Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5α- reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008;179:2333-2338.
17. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90:1502-1510.
18. Loke YK, Ho R, Smith M, et al. Systematic review evaluating cardiovascular events of the 5-α reductase inhibitor - Dutasteride. J Clin Pharm Ther. 2013;38:405-415.